A research scientist at a laboratory of a pharmaceutical company in US. Reuters
Novartis is buying dry-eye medicine brand ‘Xiidra’ from Takeda Pharmaceutical for up to $5.3 billion as the Swiss pharma-maker refreshes its ophthalmic medicines portfolio with a potential blockbuster. The deal calls for $3.4 billion up front and milestone payments up to $1.9 billion, Novartis said.
South Africa’s Biovac Institute will start local production of Sanofi’s Hexaxim vaccine next year and Pfizer’s anti-pneumonia Prevnar 13 vaccine in 2021, boosting supply of life-saving drugs in its main market, its CEO said.
Swiss drugmaker Novartis on won US approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million. The Food and Drug Administration approved Zolgensma for children
The Department of Health-Abu Dhabi decided to withdraw 20 batches medical products used in catheterisation and other healthcare operations from the Emirate because of their possibility of causing serious infection to patients if they were not immediately substituted with good ones.
London's benchmark FTSE 100 index was up 1.0 per cent, in the eurozone, Frankfurt won 0.9 per cent and Paris climbed 0.8 per cent.
Spot gold was up 0.8% at $2,033.86 per ounce by 0655 GMT, after hitting a record high of $2,036.49. US gold futures rose 1.4% to $2,049.30.
The benchmark Nikkei 225 index slipped 0.26 per cent, or 58.81 points, to end at 22,514.85, while the broader Topix index inched down 0.04 per cent, or 0.55 points, to 1,554.71.
Brent crude was up by 31 cents, or 0.7%, at $44.74 a barrel by 0713 GMT. The contract rose 0.6% on Wednesday to its highest close since March 6. West Texas Intermediate oil was up by 26 cents, or 0.6%, at $41.96 a barrel. The contract ended Tuesday trading 1.7% higher, its highest close since late July.